Cargando…
Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who recei...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Particle Therapy Co-operative Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009454/ https://www.ncbi.nlm.nih.gov/pubmed/35530185 http://dx.doi.org/10.14338/IJPT-21-00016 |
_version_ | 1784687270803013632 |
---|---|
author | Bao, Alicia Barsky, Andrew R. Maxwell, Russell Bekelman, Justin E. Both, Stefan Christodouleas, John P. Deville, Curtiland Fang, Penny Tochner, Zelig A. Vapiwala, Neha |
author_facet | Bao, Alicia Barsky, Andrew R. Maxwell, Russell Bekelman, Justin E. Both, Stefan Christodouleas, John P. Deville, Curtiland Fang, Penny Tochner, Zelig A. Vapiwala, Neha |
author_sort | Bao, Alicia |
collection | PubMed |
description | PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. METHODS: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. RESULTS: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05). CONCLUSION: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies. |
format | Online Article Text |
id | pubmed-9009454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Particle Therapy Co-operative Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90094542022-05-05 Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy Bao, Alicia Barsky, Andrew R. Maxwell, Russell Bekelman, Justin E. Both, Stefan Christodouleas, John P. Deville, Curtiland Fang, Penny Tochner, Zelig A. Vapiwala, Neha Int J Part Ther Original Articles PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. METHODS: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. RESULTS: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05). CONCLUSION: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies. The Particle Therapy Co-operative Group 2021-10-20 /pmc/articles/PMC9009454/ /pubmed/35530185 http://dx.doi.org/10.14338/IJPT-21-00016 Text en ©Copyright 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/Distributed under Creative Commons CC-BY. Open Access |
spellingShingle | Original Articles Bao, Alicia Barsky, Andrew R. Maxwell, Russell Bekelman, Justin E. Both, Stefan Christodouleas, John P. Deville, Curtiland Fang, Penny Tochner, Zelig A. Vapiwala, Neha Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title_full | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title_fullStr | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title_full_unstemmed | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title_short | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
title_sort | long-term clinical outcomes in favorable risk prostate cancer patients receiving proton beam therapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009454/ https://www.ncbi.nlm.nih.gov/pubmed/35530185 http://dx.doi.org/10.14338/IJPT-21-00016 |
work_keys_str_mv | AT baoalicia longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT barskyandrewr longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT maxwellrussell longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT bekelmanjustine longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT bothstefan longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT christodouleasjohnp longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT devillecurtiland longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT fangpenny longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT tochnerzeliga longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT vapiwalaneha longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy |